Insulet Corporation
Rank #51HypergrowthPODD · Nasdaq · Healthcare
Insulet Corporation (PODD) — Rank #51 by gross profitability (GP/assets 0.61) · ROE 17.4% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001145197 · all metrics point-in-time as of the filing date.
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Show moreShow less
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- insulet.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-18 | 2024-12-31filed 2025-02-21 | 2023-12-31filed 2024-02-23 | 2022-12-31filed 2023-02-24 |
|---|---|---|---|---|
| Revenue | 2,708.1 | 2,071.6 | 1,697.1 | 1,305.3 |
| Revenue growth (YoY) | 30.7% | 22.1% | 30.0% | 18.8% |
| Cost of revenue | 768.2 | 625.9 | 537.2 | 499.7 |
| Gross profit | 1,939.9 | 1,445.7 | 1,159.9 | 805.6 |
| Gross margin | 71.6% | 69.8% | 68.3% | 61.7% |
| Selling, general & administrative | 1,165.0 | 917.2 | 734.9 | 587.8 |
| Research & development | 301.1 | 219.6 | 205.0 | 180.2 |
| Operating income | 473.8 | 308.9 | 220.0 | 37.6 |
| Operating margin | 17.5% | 14.9% | 13.0% | 2.9% |
| Interest income | 34.7 | 39.5 | 28.6 | 9.8 |
| Interest expense | — | — | 36.2 | 36.5 |
| Pre-tax income | 339.5 | 300.2 | 214.6 | 9.8 |
| Income tax expense | 92.4 | (118.1) | 8.3 | 5.2 |
| Net income | 247.1 | 418.3 | 206.3 | 4.6 |
| Net margin | 9.1% | 20.2% | 12.2% | 0.4% |
| EPS (basic) | $3.51 | $5.97 | $2.96 | $0.07 |
| EPS (diluted) | $3.48 | $5.78 | $2.94 | $0.07 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?